

**Table 1. Comparative Median Overall Survival (OS) and Progression-Free Survival (PFS) in Similar Patients (Interim Analysis Using Kaplan-Meier Estimate)**

<b>Study</b>	<b>Prior Lines of Therapy (median, range)</b>	<b>Number of Patients</b>	<b>OS (months)</b>	<b>PFS (months)</b>
BriaCell's Phase 2 study patients who received pivotal Phase 3 study formulation (since 2022)	5.5 (2-13)	25	15.6	4.1
BriaCell's Phase 2 study patients who received pivotal Phase 3 study formulation (total)	6 (2-13)	37	13.4	3.9
Bardia, A. et. al. <sup>1</sup> (TNBC)	4 (2-14)	262	6.9	1.7
Tripathy D. et. al. <sup>2</sup> (Brain metastases)	≥4 in 91%	178	7.5-7.8	1.9-2.8
O'Shaughnessy J. et. al. <sup>3</sup> non-TNBC at initial diagnosis	5 (2-14)	76	6.7	2.3
O'Shaughnessy J. et. al. <sup>3</sup> TNBC at initial diagnosis	4 (2-10)	157	6.9	1.6
Cortes et. al. <sup>4</sup>	4 (0-13)	594	9.1-9.3	1.9-2.5